Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson's Disease

Trial Profile

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa/entacapone
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCEND-PD
  • Sponsors IMPAX Laboratories
  • Most Recent Events

    • 09 Feb 2018 Results of post hoc analysis assessing the effect of concomitant medications on safety and efficacy of extended release Carbidopa-Levodopa using patient data from ADVANCE-PD and ASCEND-PD trials published in the Clinical Neuropharmacology
    • 21 Apr 2016 Results (pooled analysis of ADVANCE-PD and ASCEND-PD studies, n = 484) assessing dosing patterns during conversion to IPX066 from other levodopa formulations presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 25 Nov 2015 According to Impax Laboratories' media release, the European Commission has granted marketing approval for levodopa/carbidopa modified release combination (NUMIENT) for the symptomatic treatment of adult patients with Parkinson's disease.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top